PolyPid Ltd. (Nasdaq: PYPD) secured a $4.3 million PDUFA fee waiver for its D‑PLEX₁₀₀ New Drug Application, a regulatory milestone that reduces the cost burden as the company moves toward a rolling NDA submission by the end of March 2026.
The waiver is a small‑business exemption of the Prescription Drug User Fee Act fee, and the amount is significant for a clinical‑stage biopharma that has been operating at a loss but holds more cash than debt, giving it flexibility to fund operations into the second half of 2026.
The waiver follows the successful Phase 3 SHIELD II trial, which showed a 60 % relative risk reduction in surgical site infections for abdominal colorectal surgeries, with a p‑value of 0.0013. The trial results, combined with the FDA’s positive feedback in a December 2025 pre‑NDA meeting, support the company’s plan to pursue a rolling NDA review.
CEO Dikla Czaczkes Akselbrad said, “We are pleased to receive this PDUFA fee waiver days before our planned NDA submission. Following our landmark Phase 3 SHIELD II results and productive engagement with the FDA on our rolling NDA review approach, we continue to make significant progress toward bringing D‑PLEX₁₀₀ to market. With D‑PLEX₁₀₀ seeking to address a significant unmet need in a major surgical infection prevention market, we are in advanced stages of commercial partnership discussions for the U.S. market while preparing for what we expect to be a transformative year for PolyPid.”
The company’s PLEX platform, a biodegradable polymer‑lipid encapsulation matrix that delivers doxycycline locally for 30 days, has also earned Breakthrough Therapy Designation for SSI prevention in elective colorectal surgery. In addition to D‑PLEX₁₀₀, PolyPid is developing candidates in oncology, obesity, and diabetes, positioning it for broader growth beyond the SSI market.
Market analysts remain optimistic about PolyPid’s prospects, noting the company’s strong regulatory progress and the potential upside of its platform technology, while investors view the fee waiver as a key cost‑saving measure that could accelerate commercialization and partnership negotiations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.